WO2016169467A8 - 使用仙台病毒作为载体的抗结核杆菌疫苗 - Google Patents

使用仙台病毒作为载体的抗结核杆菌疫苗 Download PDF

Info

Publication number
WO2016169467A8
WO2016169467A8 PCT/CN2016/079660 CN2016079660W WO2016169467A8 WO 2016169467 A8 WO2016169467 A8 WO 2016169467A8 CN 2016079660 W CN2016079660 W CN 2016079660W WO 2016169467 A8 WO2016169467 A8 WO 2016169467A8
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacterium tuberculosis
sendai virus
vector
tuberculosis vaccine
vaccine
Prior art date
Application number
PCT/CN2016/079660
Other languages
English (en)
French (fr)
Other versions
WO2016169467A1 (zh
Inventor
范小勇
朱亚峰
胡志东
罗道良
Original Assignee
上海市公共卫生临床中心
株式会社爱迪药业
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海市公共卫生临床中心, 株式会社爱迪药业 filed Critical 上海市公共卫生临床中心
Priority to JP2017555692A priority Critical patent/JP6783794B2/ja
Priority to US15/568,117 priority patent/US10828359B2/en
Publication of WO2016169467A1 publication Critical patent/WO2016169467A1/zh
Priority to PH12017501916A priority patent/PH12017501916B1/en
Publication of WO2016169467A8 publication Critical patent/WO2016169467A8/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18641—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18834—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供表达结核分枝杆菌免疫优势抗原的重组仙台病毒载体疫苗，可作为治疗性和预防性抗结核疫苗使用。
PCT/CN2016/079660 2015-04-20 2016-04-19 使用仙台病毒作为载体的抗结核杆菌疫苗 WO2016169467A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2017555692A JP6783794B2 (ja) 2015-04-20 2016-04-19 ベクターとしてセンダイウイルスを用いた抗結核菌ワクチン
US15/568,117 US10828359B2 (en) 2015-04-20 2016-04-19 Anti-Mycobacterium tuberculosis vaccine using sendai virus as vector
PH12017501916A PH12017501916B1 (en) 2015-04-20 2017-10-20 Anti-mycobacterium tuberculosis vaccine using sendai virus as vector

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510187738.8 2015-04-20
CN201510187738.8A CN106063932B (zh) 2015-04-20 2015-04-20 使用仙台病毒作为载体的抗结核杆菌疫苗

Publications (2)

Publication Number Publication Date
WO2016169467A1 WO2016169467A1 (zh) 2016-10-27
WO2016169467A8 true WO2016169467A8 (zh) 2017-11-09

Family

ID=57143705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/079660 WO2016169467A1 (zh) 2015-04-20 2016-04-19 使用仙台病毒作为载体的抗结核杆菌疫苗

Country Status (5)

Country Link
US (1) US10828359B2 (zh)
JP (1) JP6783794B2 (zh)
CN (1) CN106063932B (zh)
PH (1) PH12017501916B1 (zh)
WO (1) WO2016169467A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108018298B (zh) * 2016-10-31 2023-01-20 康希诺生物股份公司 一种脂化Ag85A蛋白
JP7150241B2 (ja) * 2016-11-17 2022-10-11 国立感染症研究所長 非感染性パラミクソウイルス粒子を用いた感染症ワクチン
CN110283766B (zh) * 2019-05-13 2020-12-18 华中科技大学 一种重组卡介苗及其构建与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2001072340A1 (ja) * 2000-03-30 2004-01-08 株式会社ディナベック研究所 センダイウイルスベクターを用いたａｉｄｓウイルスワクチン
EP1586330A1 (en) * 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
JP2009001493A (ja) * 2005-09-27 2009-01-08 Nationa Hospital Organization Ｄｎａワクチン組成物
JPWO2010050585A1 (ja) * 2008-10-31 2012-03-29 ディナベック株式会社 アルツハイマー病治療用ベクター
CN102268446B (zh) * 2010-06-03 2013-01-02 上海海规生物科技有限公司 结核杆菌Ag85ab嵌合基因疫苗、其制备方法及应用
US20130302367A1 (en) * 2010-10-22 2013-11-14 Hisatoshi Shida Virus vector for prime/boost vaccines, which comprises vaccinia virus vector and sendai virus vector
CN103304670B (zh) * 2013-06-03 2015-09-16 中国人民解放军第三〇九医院 结核分枝杆菌特异性融合蛋白疫苗ab及其制备和应用

Also Published As

Publication number Publication date
PH12017501916A1 (en) 2018-03-05
WO2016169467A1 (zh) 2016-10-27
PH12017501916B1 (en) 2018-03-05
CN106063932B (zh) 2021-07-13
US20180085449A1 (en) 2018-03-29
CN106063932A (zh) 2016-11-02
JP2018513873A (ja) 2018-05-31
JP6783794B2 (ja) 2020-11-11
US10828359B2 (en) 2020-11-10

Similar Documents

Publication Publication Date Title
ZA201801657B (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
EP3122783A4 (en) Novel recombinant bi-functional fusion proteins, preparation and use thereof
EP3413926A4 (en) HIV VACCINATION AND IMMUNOTHERAPY
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
EP3112378A4 (en) Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
WO2017066706A8 (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
WO2015134368A3 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
EP3638302C0 (en) POXVIRUS VECTORS ENCODING HIV ANTIGENS AND METHODS OF USE THEREOF
EP3489354A4 (en) RECOMBINANT VACCINE VIRUS AND ITS USE
WO2015128746A3 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
WO2016169467A8 (zh) 使用仙台病毒作为载体的抗结核杆菌疫苗
WO2019086646A8 (en) Feline leukemia virus vaccine
EP3715359A4 (en) CD4-HELPER-T-CELL PITOP-FUSION PEPTIDE AND VACCINE WITH IT
EP3526236A4 (en) SIGNATURE-BASED HUMAN IMMUNODEFICIENCY VIRUS VACCINES (ENV) CONTAINING SIGNS AND METHODS OF USE THEREOF
EP3434281A4 (en) THERAPEUTIC VACCINE AGAINST HEPATITIS B BASED ON TOTALLY RECOMBINANT AND INACTIVATED HANSENULA CELLS EXPRESSING HBSAG
EP3856895A4 (en) BIHAPTENIZED AUTOLOGOUS VACCINES AND THEIR USES
WO2016141320A3 (en) Non-neuroinvasive viruses and uses thereof
WO2015139020A3 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
EP3360886A4 (en) PEPTIDE DERIVED FROM FOXM1 AND VACCINE CONTAINING IT
IL266526A (en) Recombinant virus, preparations containing it and its uses
WO2016069518A3 (en) Genetically stable replication competent sendai virus vector(s) containing and expressing optimized hiv genes
EP3452069A4 (en) Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them
EP3568148C0 (en) PEPTIDES OF MYCOBACTERIUM TUBERCULOSIS CHAPERONINE 60.1 AND USES THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16782614

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017555692

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15568117

Country of ref document: US

Ref document number: 12017501916

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16782614

Country of ref document: EP

Kind code of ref document: A1